Novartis AG ADR (NVS)vsQuoin Pharmaceuticals Ltd DRC (QNRX)
NVS
Novartis AG ADR
$137.16
+1.33%
HEALTHCARE · Cap: $260.70B
QNRX
Quoin Pharmaceuticals Ltd DRC
$6.88
+1.33%
HEALTHCARE · Cap: $14.58M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
QNRX
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for QNRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : QNRX
The strongest argument for QNRX centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : QNRX
The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
QNRX carries more volatility with a beta of 1.73 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Quoin Pharmaceuticals Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases, addressing significant unmet medical needs in the healthcare landscape. Leveraging advanced drug delivery technologies, Quoin enhances the efficacy and safety of its treatment pipeline, thereby positioning itself for impactful clinical advancements. The company emphasizes strategic collaborations and groundbreaking research initiatives, aiming to create substantial value for both patients and investors while establishing a formidable presence in the specialty pharmaceuticals sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?